Biotech

All Articles

Merck quits period 3 TIGIT test in bronchi cancer for impossibility

.Merck &amp Co.'s TIGIT plan has actually endured another misfortune. Months after shuttering a phas...

After a difficult year, Exscientia folds up into Recursion

.After a year described through pipeline hairstyles, the shift of its chief executive officer and cu...

Cullinan, after $25M bargain, hands back bispecific to Port

.Cullinan Therapy was thrilled enough with Harbour BioMed's bispecific immune system reactor that it...

A nearer look at Intense Biotech's Strong 15

.Within this week's incident of "The Leading Pipe," our team're diving in to Brutal Biotech's annual...

Lilly faces period 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's party commemorating the commendation of Alzhei...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of significant management hirings, shooting...

Lykos will definitely inquire FDA to reassess its own choice complying with denial of MDMA therapy for post-traumatic stress disorder

.Adhering to an unsatisfactory presenting for Lykos Rehabs' MDMA applicant for post-traumatic stress...

AN 2 fifty percents census, stops period 3 test after records dissatisfy

.AN2 Rehabs is rethinking its own company in response to dull midphase records, promising to lay off...

Merck pays out $700M for bispecific, snooping autoimmune opening and chance to test Amgen in cancer cells

.Merck &amp Co. is paying for $700 million beforehand to challenge Amgen in a blood stream cancer ce...

Gilead pays out J&ampJ $320M to go out licensing offer for seladelpar

.Along With Gilead Sciences on the verge of an FDA selection for its own liver illness medication se...